Indian Biomedical Equipment Manufacturer Recovers ₹1.4 Cr from Import Duty Pass-Through Gaps

A Bengaluru-headquartered Indian manufacturer of biomedical diagnostic and patient-monitoring equipment, founder-led, with revenue of ₹40 crore (~$5M) and gross margin of 38%. Sells domestically into private hospital chains and exports approximately 35% of production into Southeast Asia, Africa, and the Middle East. Inputs include imported electronic components from Taiwan and South Korea, locally sourced enclosures and assemblies, and licensed firmware from a US partner. Subject to CDSCO regulation domestically and varying medical-device regulatory regimes in export markets.

The founder-CEO observed that gross margin had compressed from 41% to 38% over two financial years despite stable revenue, stable product mix, and a 60-paise improvement in average selling price. INR had weakened approximately 7% against USD over the period, which was the standing internal explanation. The CFO suspected there was more to it but did not have the bandwidth to dismantle the cost structure.

At ₹40 crore revenue and 38% gross margin, every percentage point of margin equals ₹40 lakh (~$48K) of annual gross profit. A 3-point compression equals ₹1.2 crore (~$144K) — a material number for a 35-person business with ambitious export-led growth plans. Founders were preparing to raise a Series B; gross-margin trajectory directly affected the valuation conversation.

The business ran a small-and-medium-business ERP. Import shipments were processed by a customs house agent who handled all CHA (customs house agent) filings, duty payments, and IGST credit reconciliation. Export documentation flowed through the same CHA. Duty drawback claims were filed quarterly. AMC contracts on calibration equipment, regulatory testing services, and software licenses renewed annually based on vendor-supplied invoices — typically without competitive review.

Four structural reasons. First, CHA invoices were treated as composite figures — the line-item duty calculation was rarely audited against the bill of entry. Second, export selling prices to non-USD markets had been set during a different INR phase and were never escalated when INR weakened, even though export contracts permitted annual escalation. Third, duty drawback claims used a default category code that under-recovered against the eligible category for the actual product. Fourth, AMC vendors had compounded 8–12% annual increases that had never been benchmarked.

Six-week engagement structured to fit a small-business cadence. Week 1–2 — bill-of-entry reconstruction across 24 months of import shipments, drawback claim audit, IGST credit reconciliation. Week 3 — export pricing review against contract escalation clauses and currency-movement timeline. Week 4 — AMC and service-vendor benchmarking across calibration, regulatory testing, and software-license categories. Week 5 — vendor and CHA dispute packet preparation. Week 6 — implementation handholding with the small finance team to ensure recoveries were actually claimed.

The default category code used for drawback claims under-recovered against the correct category eligible for the actual product. The under-recovery totalled ₹38 lakh (~$46K) across 24 months. A retroactive claim was filed for the open assessment window with the customs department; ₹22 lakh (~$26K) was recovered within five months. Forward-looking drawback claims under the corrected code added an additional ₹16 lakh (~$19K) annualised.

Export contracts to three Southeast Asian distributors and two African distributors permitted annual pricing escalation tied to INR depreciation and a regional medical-equipment cost index. The escalation had not been invoked for 18 months. A quantified positioning paper was prepared; four of five distributors agreed to a partial escalation effective the next quarter, recovering ₹46 lakh (~$55K) annualised. The fifth distributor moved to renewal at corrected terms 6 months later.

Calibration AMC vendor had compounded 11% annual increases over four years — 35% above market median by year-five. Competitive benchmarking yielded a 22% reduction with the incumbent (after an alternate vendor quote was provided), saving ₹8 lakh (~$10K) annually. Regulatory testing services consolidated from three vendors to two saved a further ₹6 lakh. The CHA agent had been bundling discretionary fees into composite invoices; an unbundling exercise saved ₹4 lakh annually. Total: ₹18 lakh (~$22K) annualised.

Customs department drawback re-filing initiated. Distributor pricing escalation packets prepared for each of the five export distributors with INR-movement and index reconstructions. AMC vendor renegotiations executed by the CFO with ValueXPA support. CHA agent fee unbundling formalised through a revised SLA. Total identified leakage addressed: ₹1.4 crore (~$170K), comprising ₹22 lakh (~$26K) recovered cash and ₹1.18 crore (~$144K) annualised forward-looking recovery.

₹22 lakh (~$26K) cash recovered within 5 months. ₹1.18 crore (~$144K) annualised recurring savings. Approximately 3 points of gross-margin recovery, restoring margin from 38% back toward 41%. Engagement payback: under 4 months. Series B raise positioning materially strengthened by the corrected margin trajectory and the demonstrated discipline around cost structure.

Bill-of-entry-level audit of import duty calculation now done monthly by the small finance team using a one-page checklist. Annual export pricing review built into the calendar with INR-trigger thresholds. AMC and service-vendor benchmarking every 24 months. CHA SLA reviewed annually. ValueXPA retained for an annual diagnostic refresh covering import duty, export pricing, and AMC categories.

Is a Margin Drift Diagnostic worth doing at $5M revenue?

Yes. The structural sources of leakage — duty mispricing, indexed pricing gaps, AMC compounding — exist regardless of revenue size. At smaller scale, the dollar amounts are smaller but the percentage-of-EBITDA impact is often larger because finance bandwidth to manage these structurally is constrained.

How long did the engagement take given the small finance team?

Six weeks of fixed-scope work, structured to fit a small-business cadence. The engagement included implementation handholding to ensure recoveries were actually claimed by the in-house team, not just identified on paper.

What was the ROI?

Engagement fee was a small fraction of the ₹1.4 crore (~$170K) addressed leakage. First-year ROI exceeded 15 times the engagement cost. Multi-year ROI is significantly higher because the export pricing escalation, drawback recategorisation, and AMC repricing are structurally durable.

Are duty drawback misclassifications common in Indian medical device exports?

Yes. Medical device categories under the drawback schedule are frequently misapplied because CHA agents default to broad codes for filing speed. A focused review against the actual product specification almost always identifies a higher-yield eligible category for at least part of the export portfolio.